Published in Retrovirology on August 24, 2012
The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int (2013) 1.11
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
Systems immunogenetics of vaccines. Semin Immunol (2013) 0.82
Genetic variation and HIV-associated neurologic disease. Adv Virus Res (2013) 0.81
Association of Toll-like receptor polymorphisms with HIV status in North Americans. Genes Immun (2014) 0.80
African ancestry influences CCR5 -2459G>A genotype-associated virologic success of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.79
HIV-1 Promoter Single Nucleotide Polymorphisms Are Associated with Clinical Disease Severity. PLoS One (2016) 0.79
Novel Neuroimaging Methods to Understand How HIV Affects the Brain. Curr HIV/AIDS Rep (2015) 0.79
The role of host genetic factors in respiratory tract infectious diseases: systematic review, meta-analyses and field synopsis. Sci Rep (2015) 0.78
Mass spectrometry-based proteomic approaches for discovery of HIV-host interactions. Future Virol (2014) 0.76
Biomarkers of HIV Susceptibility and Disease Progression. EBioMedicine (2014) 0.75
Protective Effect of HLA-B*5701 and HLA-C -35 Genetic Variants in HIV-Positive Caucasians from Northern Poland. PLoS One (2015) 0.75
Psoriasis risk SNPs and their association with HIV-1 control. Hum Immunol (2016) 0.75
CCR2, CCR5, and CXCL12 variation and HIV/AIDS in Papua New Guinea. Infect Genet Evol (2015) 0.75
Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers. Yale J Biol Med (2017) 0.75
Enrichment of HLA Types and Single-Nucleotide Polymorphism Associated With Non-progression in a Strictly Defined Cohort of HIV-1 Controllers. Front Immunol (2017) 0.75
The International HapMap Project. Nature (2003) 73.65
Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A (2009) 54.68
Finishing the euchromatic sequence of the human genome. Nature (2004) 41.40
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A (2000) 11.51
Genomewide association studies and assessment of the risk of disease. N Engl J Med (2010) 11.51
Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science (1995) 10.02
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother (2005) 7.42
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med (1993) 7.21
African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet (2008) 6.06
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Whole genome genotyping technologies on the BeadArray platform. Biotechnol J (2007) 3.61
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med (1998) 3.15
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med (2005) 2.97
Host determinants of HIV-1 control in African Americans. J Infect Dis (2010) 2.90
Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis (2009) 2.53
Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature (2011) 2.36
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One (2008) 2.14
Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med (1998) 2.01
Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol (2007) 1.89
HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PLoS One (2008) 1.69
Genomewide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS Genomewide Association Study 03). J Infect Dis (2009) 1.57
HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics (2009) 1.55
Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS (2009) 1.48
Host genetics and HIV-1 viral load set-point in African-Americans. AIDS (2009) 1.37
Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. PLoS One (2011) 1.35
Multistage genomewide association study identifies a locus at 1q41 associated with rate of HIV-1 disease progression to clinical AIDS. J Infect Dis (2010) 1.33
Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. AIDS (2011) 1.33
Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. J Infect Dis (2010) 1.16
Genome-wide association study implicates PARD3B-based AIDS restriction. J Infect Dis (2011) 1.15
32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes. Lancet (1997) 1.10
The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS (1998) 1.07
Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis (1998) 1.07
Host genetics and HIV-1: the final phase? PLoS Pathog (2010) 1.06
Regulation of MCP-1 gene transcription by Smads and HIV-1 Tat in human glial cells. Virology (2003) 1.03
A whole genome association study of mother-to-child transmission of HIV in Malawi. Genome Med (2010) 0.99
Protective effect of interleukin-4 -589T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load. J Infect Dis (2002) 0.97
Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin Infect Dis (2011) 0.95
Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol (2000) 0.92
Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol (2005) 0.91
Repression of interferon-gamma expression in T cells by Prospero-related homeobox protein. Cell Res (2008) 0.90
Protective effects of IL4-589T and RANTES-28G on HIV-1 disease progression in infected Thai females. AIDS (2006) 0.88
Genome-wide association scan in HIV-1-infected individuals identifying variants influencing disease course. PLoS One (2011) 0.88
Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophages. PLoS One (2011) 0.87
Genetic effects on HIV disease progression. Nat Med (1998) 0.81
Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Pharmacogenomics (2004) 0.81
Association between an interleukin-4 promoter polymorphism and the acquisition of CXCR4 using HIV-1 variants. AIDS (2003) 0.80
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol (2003) 4.56
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J Infect Dis (2005) 2.33
Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol (2008) 2.16
A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol (2006) 2.05
International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis (2010) 1.95
Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol (2007) 1.89
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81
Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev (2003) 1.75
HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. J Infect Dis (2008) 1.70
Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J Virol (2003) 1.57
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS (2008) 1.56
Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol (2005) 1.56
The development of CD4 binding site antibodies during HIV-1 infection. J Virol (2012) 1.53
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med (2012) 1.52
Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS (2009) 1.48
The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog (2008) 1.41
Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol (2007) 1.35
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS (2009) 1.31
Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. Nat Protoc (2008) 1.26
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med (2010) 1.26
CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog (2011) 1.26
Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J Virol (2010) 1.21
Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models. Mol Biol Evol (2010) 1.16
Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. J Infect Dis (2010) 1.16
Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog (2011) 1.15
Genome-wide association study implicates PARD3B-based AIDS restriction. J Infect Dis (2011) 1.15
Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J Virol (2007) 1.14
Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J Virol (2011) 1.14
Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. AIDS (2002) 1.13
Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol (2004) 1.13
Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J Virol (2011) 1.13
Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J Virol (2011) 1.12
Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J Infect Dis (2003) 1.11
Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour. AIDS (2004) 1.10
Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. Clin Infect Dis (2008) 1.09
Evidence for limited genetic compartmentalization of HIV-1 between lung and blood. PLoS One (2009) 1.09
Clinical significance of HIV-1 coreceptor usage. J Transl Med (2011) 1.07
Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: evidence for recombination. Virology (2003) 1.04
Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays. Antimicrob Agents Chemother (2009) 1.04
In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. J Virol (2004) 1.03
Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus. Virology (2005) 1.01
The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase. AIDS (2007) 1.01
Reconstructing the dynamics of HIV evolution within hosts from serial deep sequence data. PLoS Comput Biol (2012) 1.00
Donor variation in in vitro HIV-1 susceptibility of monocyte-derived macrophages. Virology (2009) 1.00
International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One (2012) 0.99
Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J Virol (2006) 0.98
Screening low-frequency SNPS from genome-wide association study reveals a new risk allele for progression to AIDS. J Acquir Immune Defic Syndr (2011) 0.98
Depletion of naive CD4 T cells by CXCR4-using HIV-1 variants occurs mainly through increased T-cell death and activation. AIDS (2003) 0.98
R5 human immunodeficiency virus type 1 infection of fetal thymic organ culture induces cytokine and CCR5 expression. J Virol (2005) 0.97
Molecular evolution of human immunodeficiency virus type 1 upon transmission between human leukocyte antigen disparate donor-recipient pairs. PLoS One (2008) 0.96
CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals. Virology (2005) 0.95
A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef. J Infect Dis (2008) 0.94
Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution. AIDS Res Hum Retroviruses (2003) 0.93
Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity. Virology (2009) 0.93
Prediction of residual time to AIDS and death based on markers and cofactors. J Acquir Immune Defic Syndr (2003) 0.92
Low incidence of HIV-1 superinfection even after episodes of unsafe sexual behavior of homosexual men in the Amsterdam Cohort Studies on HIV Infection and AIDS. J Infect Dis (2011) 0.92
Impact of host cell variation on the neutralization of HIV-1 in vitro. Curr Opin HIV AIDS (2009) 0.91
HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. AIDS (2004) 0.91
In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology (2006) 0.91
Cell turnover and cell tropism in HIV-1 infection. Trends Microbiol (2002) 0.90
Time-measured phylogenies of gag, pol and env sequence data reveal the direction and time interval of HIV-1 transmission. AIDS (2011) 0.90
Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. Virology (2007) 0.89
Multicohort genomewide association study reveals a new signal of protection against HIV-1 acquisition. J Infect Dis (2012) 0.89
Evaluation of pre-screening methods for the identification of HIV-1 superinfection. J Virol Methods (2010) 0.88
Genome-wide association scan in HIV-1-infected individuals identifying variants influencing disease course. PLoS One (2011) 0.88
Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic. AIDS (2011) 0.88
Causal pathways of the effects of age and the CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on AIDS development. J Acquir Immune Defic Syndr (2005) 0.88
Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. Virology (2009) 0.87
Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophages. PLoS One (2011) 0.87
Cross-reactive broadly neutralizing antibodies: timing is everything. Front Immunol (2012) 0.86
Low levels of human immunodeficiency virus type 1 DNA in high-risk seronegative men. J Virol (2005) 0.86
Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva. Eur J Oral Sci (2002) 0.86
Absence of HIV-1 superinfection 1 year after infection between 1985 and 1997 coincides with a reduction in sexual risk behavior in the seroincident Amsterdam cohort of homosexual men. Clin Infect Dis (2010) 0.86
HIV-1 envelope diversity 1 year after seroconversion predicts subsequent disease progression. AIDS (2012) 0.86
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis (2013) 0.85
Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors. Antivir Ther (2005) 0.85
Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals. PLoS One (2013) 0.85